Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes.

Trial Profile

Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Soluble beta 1,3-1,6 glucan (Primary)
  • Indications Diabetic foot ulcer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 May 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2008-003636-38).
    • 23 Nov 2009 Status changed from active, no longer recruiting to completed, according to a Biotec Pharmacon media release.
    • 23 Nov 2009 Primary endpoint 'Ulcer healing' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top